- Ixekizumab (Taltz) clearance rates are superior to those achieved with fumaric acid esters (FAEs) and methotrexate in patients with moderate to severe plaque psoriasis.
Why this matters
- This is the first head-to-head trial comparing these commonly used therapies.
- Ixekizumab was associated with a higher rate of ≥75% improvement in the Psoriasis Area and Severity Index (PASI-75; 90.7%) compared with methotrexate (70.4%; P=.0137) and FAEs (22.2%; P<.0001>
- Ixekizumab was also associated with higher rates of PASI-90 (79.6% vs 38.9% for methotrexate [P<.0001 and for faes pasi-100 vs methotrexate>
- 3.7% of patients treated with ixekizumab, 0% of patients treated with methotrexate, and 38.5% of patients treated with FAEs discontinued because of adverse events during the treatment period (P=.4954 for ixekizumab vs methotrexate; P<.0001 for ixekizumab vs methotrexate>
- 162 patients with moderate to severe plaque psoriasis who had not previously received systemic treatment: 54 received ixekizumab, 54 were treated with FAEs, and 54 received methotrexate.
- Funding: Eli Lilly.
- Relatively small sample size.
- Open-label study design.